首站-论文投稿智能助手
典型文献
CSCO guidelines for colorectal cancer version 2022:Updates and discussions
文献摘要:
Colorectal cancer(CRC)is the third most common cancer worldwide and the second most common in tumor-related mortality by Global Cancer Statistics 2020(1).Recent data show that the incidence and mortality of CRC in China are increasing(2-4),with the number of new cases and deaths reaching 607,900 and 261,777 in 2019.The Chinese Society of Clinical Oncology(CSCO)published the first version guidelines in April 2017 and updated annually according to the latest clinical data and the changes in China's national conditions(5-8).Here we present the main updates of the 2022 version compared with the previous version.
文献关键词:
作者姓名:
Zhijun Yuan;Shanshan Weng;Chenyang Ye;Hanguang Hu;Suzhan Zhang;Ying Yuan
作者机构:
Department of Radiation Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Medical Oncology,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Colorectal Surgery and Oncology,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Cancer Center,Zhejiang University,Hangzhou 310058,China
引用格式:
[1]Zhijun Yuan;Shanshan Weng;Chenyang Ye;Hanguang Hu;Suzhan Zhang;Ying Yuan-.CSCO guidelines for colorectal cancer version 2022:Updates and discussions)[J].中国癌症研究(英文版),2022(02):67-70
A类:
B类:
CSCO,guidelines,colorectal,cancer,version,Updates,discussions,Colorectal,CRC,third,most,common,worldwide,second,tumor,related,mortality,by,Global,Cancer,Statistics,Recent,data,show,that,incidence,China,increasing,number,new,cases,deaths,reaching,Chinese,Society,Clinical,Oncology,published,first,April,updated,annually,according,latest,clinical,changes,national,conditions,Here,we,present,main,updates,compared,previous
AB值:
0.661728
相似文献
Chinese clinical practice guidelines for ultrasound-guided irreversible electroporation of liver cancer(version 2022)
Min Xu;Li-Ting Xie;Yue-Yong Xiao;Ping Liang;Qi-Yu Zhao;Zhong-Min Wang;Wei-Lu Chai;Ying-Tian Wei;Lin-Feng Xu;Xiao-Kun Hu;Ming Kuang;Li-Zhi Niu;Chen-Guo Yao;Hai-Ying Kong;Guo Tian;Xiao-Yan Xie;Xin-Wu Cui;Dong Xu;Jun Zhao;Tian-An Jiang;The Interventional Diagnosis and Treatment Group of the Ultrasonic Medicine Branch of Chinese Medical Association;The Nanoknife Tumor Ablation Society of the Interventional Minimally Invasive Therapy Special Committee of China Medicine Education Association-Department of Ultrasound Medicine,First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Key Laboratory of Pulsed Power Translational Medicine of Zhejiang Province,Hangzhou,Zhejiang 310003,China;Department of Radiology,The First Medical Center,Chinese PLA General Hospital,Beijing 100000,China;Department of Radiology,The Fifth Medical Center,Chinese PLA General Hospital,Beijing 100853,China;Department of Interventional Radiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Interventional Radiology,Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University,Guangzhou 510120,China;Department of the Interventional Medical Center,the Affiliated Hospital of Qingdao University,Qingdao 266000,China;Division of Interventional Ultrasound,The First Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510080,China;Department of Oncology,Affiliated Fuda Cancer Hospital,Jinan University,Guangzhou 510665,China;School of Electrical Engineering,Chongqing University,Chongqing 400033,China;Department of Anesthesiology,First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Medical Ultrasonics,Institute of Diagnostic and Interventional Ultrasound,The First Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510080,China;Department of Medical Ultrasound,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Interventional Ultrasound,The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Basic Medicine and Cancer(IBMC),Chinese Academy of Sciences,Hangzhou 310022,China;Department of Anatomy,School of Basic Medicine,Huazhong University of Science and Technology,Wuhan 430030,China
Disability-adjusted life years and the trends of the burden of colorectal cancer: a population-based study in Shanghai, China during 2002 to 2016
Zhong Wei;Chen Liping;Li Xiaopan;Chen Yichen;Zhang Yao;Guo Canjie;Shen Yufeng;Chen Huimin-Department of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200001, China;Department of Internal Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200001, China;Department of Health Management Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Center for Disease Control and Prevention, Fudan University Pudong Institute of Preventive Medicine, Shanghai 200136, China
ZNF3 regulates proliferation,migration and invasion through MMP1 and TWIST in colorectal cancer
Le Du;Ning Liu;Jianfeng Jin;Meng Cao;Yuantian Sun;Xinzheng Gao;Banzhan Ruan;Shangfeng Yang;Dongsheng Ge;Yingzhuan Ye;Yinxi Zhou;Erfei Chen;Jin Yang-Hainan Provincial Key Laboratory of Carcinogenesis and Intervention;Department of Biology,Hainan Medical University,Haikou 571199,China;Department of Gastrointestinal Surgery,Hainan General Hospital,Hainan Affiliated Hospital of Hainan Medical University,Haikou 571199,China;Department of Biochemistry and Molecular Biology,Hainan Medical University,Haikou 571199,China;College of Biomedical Information and Engineering,Hainan Medical University,Haikou 571199,China;Key Laboratory of Resources Biology and Biotechnology in Western China,Ministry of Education,College of Life Sciences,Northwest University,Xi'an 710069,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。